Retatrutide
Retatrutide
A triple-hormone receptor agonist developed by Eli Lilly that activates GLP-1, GIP, and glucagon receptors at the same time. Phase 2 trials published in the New England Journal of Medicine and The Lancet showed roughly 24% average weight loss and 2-point HbA1c drops, bigger effect sizes than anything currently approved in this class. Phase 3 (TRIUMPH-4) results have been announced via Eli Lilly press release but are not yet fully published, and the compound is not yet FDA-approved.
Strong animal and lab research
For education only.Information about Retatrutide is for education only. Doses, routes, and protocols must come from a licensed healthcare provider familiar with your individual medical history. More.
Significant Weight Loss
Phase 2 trial of 338 adults with obesity (NEJM, 2023) showed about 24% average body-weight loss over 48 weeks at the highest dose. Every patient in that dose group lost at least 5%, and 83% lost 15% or more. Phase 3 press release suggests up to 28% at 68 weeks (full data not yet published).
Blood Sugar Control
Phase 2 trial of 281 adults with type 2 diabetes (The Lancet, 2023) showed a 2.2-point HbA1c reduction at the highest dose over 36 weeks, beating dulaglutide (1.3 points) and placebo (0.4 points). Tested in a double-blind, placebo-controlled, active-comparator design.
Liver Fat Reduction
A 98-person substudy in Nature Medicine (2024) showed an 86% average reduction in liver fat content at 48 weeks, with 93% reaching normal liver-fat levels. Important caveat: this measured fat content on MRI, not whether liver disease (scarring or inflammation) is actually reversing. No biopsies were taken.
Body Composition
A 163-person DXA-scan substudy showed roughly 75% of weight lost was fat (about 25% lean tissue), in line with tirzepatide. Visceral fat dropped about 45% versus 2% on placebo. Note: DXA "lean tissue" includes water, bone, and organs, so muscle preservation isn't directly confirmed.
Not medical advice. Talk to a licensed provider.